Ignite Creation Date:
2024-05-06 @ 7:42 AM
Last Modification Date:
2024-10-26 @ 11:51 AM
Study NCT ID:
NCT02581007
Status:
COMPLETED
Last Update Posted:
2023-04-27
First Post:
2015-10-16
Brief Title:
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Sponsor:
Northside Hospital Inc
Organization:
Northside Hospital Inc
Study Overview
Official Title:
Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source The primary objective of the study is to estimate the incidence of graft rejection and acute GVHD A secondary objective will be to estimate the incidence of the relapse NRM OS chronic GVHD and EFS
Detailed Description:
Patients will receive a haploidentical transpalnt using a fludarabine melphalan prepartive regimen Patients will get cyclophosphamide on days 3 4 post-transplant
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None